GENUS PLC (GNS) — Investment Research Note

Executive summary

Genus is a world-leading animal genetics company that sells proprietary pig (PIC) and cattle (ABS) breeding genetics and semen into livestock producers worldwide, earning a mix of upfront animal sales and recurring royalty revenue. After a mid-cycle trough in FY24 (adj PBT £59.8m) driven by Chinese pork market volatility and ABS softness, the group has returned to double-digit profit growth — H1 FY26 adjusted PBT grew 57% YoY and the FY26 trading update (14 July 2026) flags adj PBT of ~£98m, moderately ahead of consensus. The single most important valuation point today is that the Chinese porcine JV formation (31 January 2026) has deconsolidated a volatile asset while handing Genus ~£111m of net cash and dropping leverage to ~0.4x — unlocking balance-sheet optionality but also reducing the consolidated revenue base.

Fair value estimate

Methodology: Forward P/E anchored to normalised earnings, cross-checked with EV/EBITDA.

Key inputs:

• FY26A adj PBT ~£98m → adj PAT ~£71m at 27.8% tax rate → adj EPS ~108p
• Post PIC-China deconsolidation, FY27 run-rate loses PIC China operating profit (~£8–10m) but gains JV equity income; group ongoing adj EPS likely in the 95–110p range
• Rolling 12m adj EPS at H1 FY26 reporting was 102.8p

Fair value range (per share, pence):

• Bear: 15x FY27E EPS of ~100p = 1,500p (£980m)
• Base: 20x FY27E EPS of ~105p = 2,100p (£1,370m)
• Bull: 23x FY27E EPS of ~110p = 2,530p (£1,650m)

Mid-point market cap: £1,370m vs current £1,490m. Absolute return vs current 2,280p: –8% at midpoint (fair-to-slightly-expensive, ~2% upside to bull, 34% downside to bear).

The stock has already re-rated — it printed 3,170p in January 2026 on PRP optimism and has retraced ~28% since.

Sector context

Confirmed as Health Care / Health Care per ICB, though commercially this is an agricultural biotechnology / animal science business, often grouped with specialty agriculture. Quality is above typical healthcare peers in terms of recurring royalty economics but growth and profitability are more cyclical. The clearest listed comparators are Vilmorin (plant genetics, now private), Alltech (private), and Zoetis (ZTS, animal health, more diversified and higher-multiple). Genus trades at a discount to Zoetis given smaller scale and livestock-cycle exposure.

Investment thesis

1. Royalty-model operating leverage is now visible. H1 FY26 showed revenue flat at £335.6m but adj operating margin expanded 580bps to 19.2%, with adj operating profit (inc. JVs) up 42% — royalty revenue grew 7% in constant currency to £93m, demonstrating the long-tail compounding effect 2026-02-26 interim results.
2. De-risked China exposure with cash dividend. The 31-Jan-2026 BCA JV formation delivered ~£111m net cash in Q4 FY26 and cut net leverage to ~0.4x, while retaining 49% in the Chinese upside 2026-07-14 FY26 trading update. ABS Value Acceleration Programme (VAP) Phase 3 is delivering ~£7m in-year/£9m annualised savings 2026-02-26 interim.
3. PRP optionality — Canada approved Jan 2026, Mexico/Japan still needed. The PRRS Resistant Pig has received US FDA (Apr 2025) and Canadian (Jan 2026) approvals, with the pure-line asset not yet on the balance sheet (zero carrying value) — meaningful optionality that is not in base earnings 2026-02-26 interim results.

Key risks

1. Chinese pork cycle and ASF resurgence. The business repeatedly cites China volatility (prices 10–28 RMB/kg range in recent years); H1 FY26 noted pork prices below Chinese cost of production and Spanish ASF in wild boars 2026-02-26 interim. JV insulates somewhat but equity accounting of PIC China still exposed.
2. Dairy/beef cyclicality + bovine imports blocked from US to China — ABS Asia volumes down 40% in H1 FY26 2026-02-26 interim. VAP benefits may mask continued top-line softness in bovine.
3. PRP commercialisation delay or restricted market. Multi-year regulatory path (Mexico, Japan still outstanding); every slippage pushes out the IRR 2026-02-26 interim. The stock has shown it discounts PRP optimism (3,170p peak in Jan 2026 then de-rated).

Operating leverage

Genus has a capital-light scale economics profile with meaningful operating leverage. Royalty revenue (£178m in FY25, ~27% of total) carries near-100% incremental contribution margin — once an animal is adopted in a breeding programme, the royalty stream is highly fixed in cost terms. The H1 FY26 result is the clearest proof: on flat revenue (£335.6m vs £336.4m), adj operating profit inc JVs rose 42% to £64.4m, a 580bp margin expansion. R&D (£7.1m in H1 FY26, 2% of revenue) and group central costs (£11.2m) are substantially fixed. We estimate a 10–20% revenue uplift (particularly in royalty-mix revenue) would plausibly add 50–80% to adjusted operating profit at current scale, given gross margins in PIC of ~35% (adj op margin exc JV) and ABS structural margin expansion from VAP. Capacity-constrained elite genetic farms (Aurora, Atlas, LuoDian) provide a fixed-cost base that benefits from utilisation gains 2026-02-26 interim.

Value-trap signals

None identified. Balance sheet is strong, dividend is covered and growing (FY26 interim 11.2p +9%), earnings are rising, no related-party or going-concern flags, and the industry is secular rather than terminal-decline.

Earnings vs. expectations

Looking across the 5-year filing set: FY23 saw a profit warning in May 2023 as PIC China weakened (H1 beat but H2 cut). FY24 saw further guidance reduction in Feb 2024 (£58m vs higher) due to ABS and China. FY25 came in ahead (July 2025 update: ≥£72m vs £67.9m consensus midpoint), H1 FY26 came in ahead (Jan 2026 update: ~£55.6m vs expectations), and FY26 full-year came in ahead (July 2026 update: ~£98m vs £95.5m consensus midpoint). The pattern: 2 misses in FY23–FY24 followed by 3 consecutive beats under new CEO Jorgen Kokke since 2024. Trend is clearly improving.

Conviction

4 — high. Anchors: (i) clean, well-disclosed segmental financials with consistent APM reconciliations; (ii) multiple convergent methodologies (P/E, EV/EBITDA, DCF would all land in a similar range given the stable royalty model); (iii) recent trading has beaten guidance three times running, improving forecast reliability. Caveats: (i) PIC China deconsolidation creates a one-year noisy comparable in FY27; (ii) PRP optionality value is genuinely binary — the stock could re-rate significantly on Mexico/Japan approvals.